Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established therapy for Parkinson's disease (PD) [1]. However, determining the optimal stimulation setting can be a time-consuming trial-and-error process. Thus, there is a need to define non-invasive biomarkers, for instance through the analysis of DBS-evoked cortical responses (CR) [2]. Previous studies indicate that CR with latencies of 2–10 ms – resulting from antidromic hyperdirect pathway activation – are higher for stimulation contacts that elicit a therapeutic effect [3].
No takes yet. Share an insight, caveat, or question.
Bahners et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: